Inventor · disambiguated record
Matthew Sleeman
Also filed as: SLEEMAN MATTHEW · SLEEMAN MATTHEW ALEXANDER
19 granted patents·16 pending applications·47 citations·filing 2001–2024
92Inventor score
Files withMEDIMMUNE LTD15REGENERON PHARMA8GENESIS RES & DEV CORP LTD7COHEN EMMA SUZANNE2COCHRANE DUNCAN1
Top patents by PatentIndex Score
35 records- 0191US11787867B2Anti-GITR antibodies and uses thereofREGENERON PHARMA·Filed 2021·Granted Oct 17, 2023·2 cites·24 claims
- 0287US2024124596A1Antibody molecule for human gm-csf receptor alphaMEDIMMUNE LTD·Filed 2023·Application pending·0 cites
- 0384US9884911B2Compounds and methods for treating painMEDIMMUNE LTD·Filed 2015·Granted Feb 6, 2018·4 cites·16 claims
- 0484US8263075B2Antibody molecule for human GM-CSF receptor alphaCOHEN EMMA SUZANNE·Filed 2007·Granted Sep 11, 2012·6 cites·10 claims
- 0584US2024262902A1Compounds and methods for treating painMEDIMMUNE LTD·Filed 2024·Application pending·0 cites
- 0683US8506960B2Antibody molecule for human GM-CSF receptor alphaCOHEN EMMA SUZANNE·Filed 2007·Granted Aug 13, 2013·5 cites·15 claims
- 0782US11053307B2Compounds and methods for treating painMEDIMMUNE LTD·Filed 2019·Granted Jul 6, 2021·1 cites·24 claims
- 0881US11377502B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Jul 5, 2022·1 cites·5 claims
- 0981US10668150B2IL33 form, mutated forms of IL33, antibodies, assays and methods of using the sameMEDIMMUNE LTD·Filed 2016·Granted Jun 2, 2020·3 cites·13 claims
- 1080US10457728B2Compounds and methods for treating painMEDIMMUNE LTD·Filed 2017·Granted Oct 29, 2019·2 cites·19 claims
- 1178US11738081B2Polynucleotides encoding IL33 antibodies and methods of using the sameMEDIMMUNE LTD·Filed 2020·Granted Aug 29, 2023·1 cites·15 claims
- 1277US12331127B2Therapeutic uses of anti-GITR antibodiesREGENERON PHARMA·Filed 2023·Granted Jun 17, 2025·0 cites·55 claims
- 1377US9085628B2Antibody molecule for human GM-CSF receptor alphaMEDIMMUNE LTD·Filed 2013·Granted Jul 21, 2015·2 cites·16 claims
- 1477US2025171622A1Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonistsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1576US7083791B2Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptidesGENESIS RES & DEV CORP LTD·Filed 2003·Granted Aug 1, 2006·13 cites·5 claims
- 1675US11897949B2Compounds and methods for treating painMEDIMMUNE LTD·Filed 2021·Granted Feb 13, 2024·0 cites·23 claims
- 1774US8865166B2Antibodies to IL-17A and uses thereofCOCHRANE DUNCAN·Filed 2007·Granted Oct 21, 2014·6 cites·8 claims
- 1874US2021147559A1Antibody molecule for human gm-csf receptor alphaMEDIMMUNE LTD·Filed 2020·Application pending·0 cites
- 1973US2024390460A1Antibody resistant modified receptors to enhance cell-based therapiesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2072US2024016929A1Il33 antibodies and methods of using the sameMEDIMMUNE LTD·Filed 2023·Application pending·0 cites
- 2168US12497460B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Dec 16, 2025·0 cites·30 claims
- 2267US2019309077A1Antibody molecule for human gm-csf receptor alphaMEDIMMUNE LTD·Filed 2019·Application pending·0 cites
- 2366US12209180B2Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonistsREGENERON PHARMA·Filed 2019·Granted Jan 28, 2025·0 cites·45 claims
- 2466US9315571B2Specific binding members for NGFFRANKS RUTH·Filed 2006·Granted Apr 19, 2016·1 cites·9 claims
- 2565US2019040145A1Antibody molecule for human gm-csf receptor alphaMEDIMMUNE LTD·Filed 2018·Application pending·0 cites
- 2657US2015376285A1Antibody Molecule For Human GM-CSF Receptor AlphaMEDIMMUNE LTD·Filed 2015·Application pending·0 cites
- 2756US2023349919A1Methods Of Mapping Antigen Specificity To Antibody-Secreting CellsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2847US9701746B2Methods of treating neuropathic pain with specific binding members for NGFMEDIMMUNE LTD·Filed 2016·Granted Jul 11, 2017·0 cites·6 claims
- 2946US6797271B2Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptidesGENESIS RES & DEV CORP LTD·Filed 2001·Granted Sep 28, 2004·0 cites·15 claims
- 3046US2003022835A1Compositions isolated from skin cells and methods for their useGENESIS RES & DEV CORP LTD·Filed 2002·Application pending·0 cites
- 3143US2003040471A1Compositions isolated from skin cells and methods for their useFiled 2001·Application pending·0 cites
- 3241US2005112642A1Fibroblast growth factor receptors and methods for their useGENESIS RES & DEV CORP LTD·Filed 2004·Application pending·0 cites
- 3341US2005009750A1Fibroblast growth factor receptors and methods for their useGENESIS RES & DEV CORP LTD·Filed 2004·Application pending·0 cites
- 3436US2003143676A1Fibroblast growth factor receptors and methods for their useGENESIS RES & DEV CORP LTD·Filed 2002·Application pending·0 cites
- 3533US2006115483A1Fibroblast growth factor receptors and methods for their useGENESIS RES & DEV CORP LTD·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew Sleeman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →